Friday, August 15, 2014 5:37:00 PM
NEW YORK (TheStreet) -- Ironwood Pharmaceuticals (IRWD_) was falling -8.2% to $13.63 Tuesday after missing analysts estimates for earnings and revenue for the second quarter.
The company reported a loss of -38 cents a share for the second quarter, missing the Capital IQ Consensus Estimate of -36 cents a share by 2 cents. Revenue fell -29.2$ year-over-year to $6.84 million for the quarter. Analysts expected revenue of $15.75 million in the quarter.
The Street Ratings team rates IRONWOOD PHARMACEUTICALS INC as a Sell with a ratings score of D. The Street Ratings Team has this to say about their recommendation:
"We rate IRONWOOD PHARMACEUTICALS INC (IRWD) a SELL. This is driven by multiple weaknesses, which we believe should have a greater impact than any strengths, and could make it more difficult for investors to achieve positive results compared to most of the stocks we cover. The area that we feel has been the company's primary weakness has been its deteriorating net income."
Recent IRWD News
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/12/2024 08:05:03 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/10/2024 08:58:50 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 06/10/2024 08:57:11 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 06/07/2024 05:35:18 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 06/06/2024 07:57:27 PM
- Ironwood Pharmaceuticals to Participate in the Jefferies Global Healthcare Conference • Business Wire • 05/30/2024 08:01:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/22/2024 08:05:26 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/22/2024 08:05:19 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/22/2024 08:05:12 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/22/2024 08:05:09 PM
- Ironwood Late-Breaker Oral Presentation at Digestive Disease Week® Reinforces Potential of Once-Weekly Apraglutide for Adults with Short Bowel Syndrome with Intestinal Failure (SBS-IF) • Business Wire • 05/21/2024 10:00:00 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/20/2024 08:05:24 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 05/17/2024 08:11:19 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 05/17/2024 08:08:55 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 05/17/2024 08:07:31 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 05/17/2024 08:04:58 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/09/2024 08:46:11 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/09/2024 11:09:10 AM
- Ironwood Pharmaceuticals Reports First Quarter 2024 Results • Business Wire • 05/09/2024 11:00:00 AM
- Ironwood Pharmaceuticals to Participate in The Citizens JMP Life Sciences Conference • Business Wire • 05/06/2024 08:01:00 PM
- Ironwood Pharmaceuticals to Present New Data on Once-Weekly Apraglutide in Short Bowel Syndrome with Intestinal Failure (SBS-IF) at Digestive Disease Week® 2024 • Business Wire • 05/01/2024 11:30:00 AM
- Ironwood Pharmaceuticals to Host First Quarter 2024 Investor Update Call • Business Wire • 04/25/2024 08:01:00 PM
- Ironwood Pharmaceuticals Announces Positive Results from its Phase II Exploratory STARGAZE Trial of Apraglutide in Patients with Steroid-Refractory Gastrointestinal Acute Graft-versus-Host Disease (SR GI aGVHD) • Business Wire • 03/28/2024 11:30:00 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/08/2024 09:05:19 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/07/2024 09:05:10 PM
ECGI Holdings Announces LOI to Acquire Pacific Saddlery to Capitalize on $12.72 Billion Market Potential • ECGI • Jun 13, 2024 9:50 AM
Fifty 1 Labs, Inc. Announces Major Strategic Advancements and Shareholder Updates • CAFI • Jun 13, 2024 8:45 AM
Snakes & Lattes Opens Pop-Up Location at The Wellington Market in Toronto: A New Destination for Fun and Games - Thanks 'The Well', PepsiCo, Indie Pale House & All Sponsors & Partners for Their Commitment & Assistance Throughout The Process • FUNN • Jun 13, 2024 8:18 AM
HealthLynked Introduces Innovative Online Medical Record Request Form Using DocuSign • HLYK • Jun 12, 2024 8:00 AM
Ubiquitech Software Corp (OTC:UBQU) Posts $624,585 Quarterly Revenue - Largest Quarter Since 2018 • UBQU • Jun 11, 2024 10:13 AM
Element79 Gold Corp Files for OTCQB Uplisting, Provides Financial Update • ELEM • Jun 11, 2024 9:25 AM